Novacea news from FierceBiotech
NewsNovacea cuts staff after partner dumps collaboration
A month after Schering-Plough pulled the plug on its collaboration with Novacea for a new prostate cancer therapy--Read more...
ALSO NOTED: FDA approves Orencia; Delay on Amgen clotting drug decision; Icahn files suit for Biogen Idec papers; and much more
> The FDA has approved Bristol-Myers Squibb's Orencia for juvenile arthritis. Read more...
Novacea slows down development program for AQ4N
Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a Read more...
Novacea ends Asentar trial, shares plunge
Novacea has shuttered its Phase III trial of the prostate cancer drug Asentar, citing an "imbalance of death" recorded in the two arms of the study. Novacea and partner Schering-Plough say that they Read more...
ALSO NOTED: EU panel recommends Bayer, GSK drugs; Novacea names new CEO; and much more...
> An EMEA advisory panel has issued six positive opinions on marketing applications for new drugs, paving the way for EU marketing approval. Read more...
Novacea cheered on decision to expand cancer trial
Novacea has disclosed that it has asked the FDA to boost enrollment in a late-stage trial of its prostate cancer drug, Asentar. The company, which reported widening second-quarter losses as a result Read more...
| Press ReleasesNovacea Reports First Quarter 2008 Financial ResultsNovacea Reports First Quarter 2008 Financial Results Company Announces Reduction in Workforce to Focus on Managing Capital Resources SOUTH SAN FRANCISCO, CA - May 12, 2008 (MARKET WIRE via COMTEX Read more... PRESS RELEASE: Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar Novacea Halts Late-Stage Trial of Prostate Cancer Drug Asentar SOUTH SAN FRANCISCO, CA - Nov 5, 2007 -- Novacea announced today that the company has ended its Phase 3 ASCENT-2 clinical trial of Read more... PRESS RELEASE: Novacea Appoints John P. Walker as CEO Novacea Appoints John P. Walker as CEO SOUTH SAN FRANCISCO, CA -- Sep 20, 2007 -- Novacea, Inc. (NasdaqGM:NOVC - News) today announced that, effective immediately, John P. Walker has been elected as Read more... PRESS RELEASE: Novacea Reports Second Quarter 2007 Financial ResultsNovacea Reports Second Quarter 2007 Financial Results Company Provides Update On Ascent-2 Phase 3 Trial SOUTH SAN FRANCISCO, Calif., Aug. 14 -- Novacea, Inc. today reported financial results for the Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends